COMPLICATIONS OF CHRONIC KIDNEY DISEASE (CKD) BY LEVEL OF ALBUMINURIA AND PROTEINURIA IN THE IRBESARTAN IN DIABETIC NEPHROPATHY TRIAL (IDNT)

被引：0
|
作者：
Viswanathan, Gautham [1 ]
Tighiouart, Hocine [1 ]
Muntner, Paul [2 ]
Lewis, Julia [3 ]
Sarnak, Mark [1 ]
Stevens, Lesley [1 ]
机构：
[1] Tufts Med Ctr, Boston, MA USA
[2] Univ Alabama, Tuscaloosa, AL 35487 USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2011年 / 57卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A102 / A102
页数：1
相关论文
共 50 条
  • [1] Effect of baseline proteinuria and change in proteinuria with treatment on the risk of renal endpoints in the irbesartan diabetic nephropathy trial (IDNT).
    Atkins, RC
    Briganti, EM
    Wiegmann, TB
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 7A - 7A
  • [2] An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting
    Palmer, AJ
    Annemans, L
    Roze, S
    Lamotte, M
    Rodby, RA
    Bilous, RW
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (10) : 733 - 738
  • [3] An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting
    A J Palmer
    L Annemans
    S Roze
    M Lamotte
    R A Rodby
    R W Bilous
    [J]. Journal of Human Hypertension, 2004, 18 : 733 - 738
  • [4] Clinical Trial Design Based on Disease Progression and Pharmacological Effects in the Irbesartan Diabetic Nephropathy Trial (IDNT)
    Chan, Phyllis
    Chen, Chunlin
    Clawson, David
    Soares, Holly
    Pupim, Lara
    LaCreta, Frank
    AbuTarif, Malaz
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S113 - S113
  • [5] Irbesartan is projected to save money while prolonging life in Type II diabetic nephropathy: A pharmacoeconomic model of the irbesartan in diabetic nephropathy trial (IDNT).
    Rodby, R
    Chen, R
    Simon, T
    Sengupta, N
    Borenstein, J
    Chiou, C
    Smitten, A
    Palmer, A
    Annemans, L
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 687A - 687A
  • [6] The health-economic implications of the "Irbesartan in Diabetic Nephropathy Trial" (IDNT) in France and Belgium
    Palmer, AJ
    Annemans, L
    Roze, S
    Lamotte, M
    Guilhaume, C
    Gabriel, S
    Carita, P
    Chen, R
    Simon, T
    Rodby, R
    Cordonnier, DJ
    [J]. VALUE IN HEALTH, 2002, 5 (06) : 546 - 546
  • [7] Cardiovascular outcomes in the irbesartan diabetic nephropathy trial (IDNT) of patients with type 2 diabetes and overt nephropathy.
    Berl, T
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 651A - 651A
  • [8] Proteinuria versus albuminuria in chronic kidney disease
    Guh, Jinn-Yuh
    [J]. NEPHROLOGY, 2010, 15 : 53 - 56
  • [9] Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial
    Hunsicker, LG
    Atkins, RC
    Lewis, JB
    Braden, G
    De Crespigny, PJC
    DeFerrari, G
    Drury, P
    Locatelli, F
    Wiegmann, TB
    Lewis, EJ
    [J]. KIDNEY INTERNATIONAL, 2004, 66 : S99 - S101
  • [10] An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings
    Palmer, AJ
    Annemans, L
    Roze, S
    Lamotte, M
    Rodby, RA
    Cordonnier, DJ
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (10) : 2059 - 2066
12345